Lena Basile, J.D., Ph.D., Founder, Chairman of the Board and Chief Executive Officer
Dr. Basile founded Neumedicines in 2003 and is the driving force behind its success. Dr. Basile wrote the original IL-12 technology patent applications and secured multiple funded peer-reviewed grants and contracts. To date, Dr. Basile has secured over $70 million in non-dilutive government funding for Neumedicines. Dr. Basile received her doctorate in chemistry from Columbia University in inorganic complex-DNA interactions. She then went on to complete postdoctoral studies at Yale University in the department of Molecular Biology and Biochemistry, where she studied protein-DNA interactions of several DNA-binding proteins including HIV-related proteins. Dr. Basile has over 20 years of scientific experience and also holds a doctorate in law from the University of Houston Law Center. She is a member of the State Bar of California and, prior to founding Neumedicines, practiced as an intellectual property attorney for 7 years.
Vladimir Vainstein, MD, MSc, Acting Chief Medical Officer
Dr. Vainstein is a board-certified hematologist and has more than 10 years of experience in research of mechanism-based pharmacodynamics modeling of hematopoiesis and anti-cancer therapies. He also performed preclinical studies of anti-angiogenic and anticancer stem cell compounds at Hebrew University, Israel and University of Southern California. Prior to joining Neumedicines, Dr. Vainstein worked as a clinical hematologist at Hadassah Medical Center, Israel, and served as clinical advisor for Optimata Ltd, Israel. Dr. Vaisntein has co-authored 12 scientific publications in peer-reviewed journals and is a co-inventor of 3 patents. He received his MD and MSc degrees from Hadassah Medical School of Hebrew University, Jerusalem, Israel.
Christopher Lawrence, PhD, Sr. Director of Research
Dr. Lawrence has over 15 years of experience in the Pharmaceutical and Biotechnology industries, occupying positions of increasing responsibility at Sanofi Pharmaceuticals, Amgen Inc., Sunesis Pharmaceuticals, and most recently as Director of Clinical Pharmacology at Xencor Inc. During that time Dr. Lawrence successfully advanced 13 small molecules and biologics into clinical trials, optimizing their pharmacological, pharmacodynamic, and pharmacokinetic properties. Dr. Lawrence was awarded his doctorate degree while researching at the Department of Immunology, Cambridge University, UK, and received his degree in Biochemistry from Newcastle University, UK.
Zoya Gluzman-Poltorak, PhD, MBA, Sr. Director of Development
Dr. Gluzman-Poltorak has more than 10 years of experience in biotechnology senior management, advancing products from early-stage research up to their regulatory approval. Prior to joining Neumedicines Inc., she was Chief Technology Officer at Gene Grafts Ltd. (2005-2009), and Angiogenesis Project Manager at MGVS Ltd.(2000-2004), both Israeli companies developing innovative genetically modified cell therapy products to address a number of vascular, cardiologic, and neurologic disorders. She has co-authored 15 peer-reviewed articles and holds a number of patents in angiogenesis, oncology, cardiology and neurology. Dr.Gluzman-Poltorak received her PhD in Cell Biology and Genetic Engineering from the Biology faculty of the Technion, Haifa, Israel, and MBA from the Industrial Engineering and Management faculty of the Technion, Haifa, Israel.
Rose Lopez, Sr. Director of Quality and GMP Operations
Rose Lopez joined Neumedicines in April 2014. She is a 25 year veteran in the biotechnology/pharmaceutical/contract clinical research service industry. She has proven expertise in leadership, global regulatory inspection strategy, operations and quality management. Ms. Lopez utilizes her broad knowledge in the practical application of GMP / GCP regulations, ISO standards, ICH guidelines, computer systems life cycle development and quality systems in a clinical phase appropriate fashion. She has served on numerous product teams in small and large companies (including Baxter, Amgen and Merck) that have successfully navigated through the commercialization process bringing several small and large molecules to market and maintaining them post approval. Ms. Lopez is a graduate of Colorado State University with a Bachelors of Science in Biological Sciences with a concentration in Microbiology.
Scott Buckel, PhD, Sr. Director of Analytical Development
Scott Buckel joined Neumedicines in September 2014 after consulting with Neumedicines for the previous 5 years. He is a veteran of 28 years in biotechnology supporting the development of several protein based pharmaceuticals. He has been involved with the commercial development of several biotech drugs as well as involved with early phase drug development. Scott has specialized in the analytical aspects, formulation and stability and regulatory aspects working for both small and large companies. He has worked for Pitman-Moore Pharmaceuticals, Parke Davis Pharmaceutical Development, Amgen and Xencor. Scott is a graduate of University of Houston and Purdue University.